Award-winning British Recycling Project, NEXTLOOPP, Hits Bullseye in Plastics Recycling Ahead of COP26
NEXTLOOPP, the groundbreaking project by Nextek Limited, that recently won the overall award for ‘Best Sustainable Packaging Innovation’ at Packaging Europe’s Sustainability Awards - https://packagingeurope.com/sustainability-awards-2021-winners-revealed/ has revealed the results of its highly successful tracer-based sorting trials held at TOMRA (Germany) in September 2021.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211020005464/en/
NEXTLOOPP participants in the global project to close the loop on food-grade Polypropylene (Graphic: Business Wire)
The trials, to specifically sort food-grade plastic packaging waste, achieved a resounding 99.9% sorting purity at maximum production speed.
This demonstrates that Nextek’s unique technology efficiently differentiates food packaging from non-food packaging to meet the standards required by the Food Standards Authorities in the UK and EU. Being able to identify and sort any number of pack variants from bleach bottles to milk bottles in any plastic type is a world-first that will transform the way we recycle the prolific volume of single-use post-consumer food packaging waste back into circular applications.
This announcement marks 12 months of NEXTLOOPP’s programme to close the loop on food-grade Polypropylene (FGPP), which is the biggest plastic fraction in the FMCG sector. In the UK alone, 210,000 tonnes of FGPP packaging is used in pots, tubs, trays and films each year, and this cutting-edge innovation creates the opportunity to recycle Polypropylene (PP) back into food packaging.
This also heralds a new era in the plastics packaging recycling industry and the validation of NEXTLOOPP’s PolyPRISMTM ‘plug-and-play’ marker system, as used on TOMRA’s sorting equipment for commercial purposes.
Sorting plastic waste into polymer types is the first of three vital steps needed to close the loop on PP and create a global low carbon economy. The next step requires splitting the plastic packaging into food and non-food fractions. The final step involves NEXTLOOPP’s patented decontamination process, PPristineTM, which unlocks the markets to food packaging. Recycling 63,000 tonnes of PP per annum would save a minimum estimated 105,600 tonnes in CO2 emissions in the UK each year.
“During recent trials held at our TOMRA Test Centre we achieved very promising results on all Polypropylene 3D samples in all test runs with state-of-the-art NIR/VIS technology. We exceeded the required 95% purity for food-grade in each test run. The next important milestones will be a field demonstration as well as demonstrating chemical compliance with food-grade regulation” said Ralph Uepping, Technical Director at TOMRA.
Professor Edward Kosior, founder of Nextek, believes the NEXTLOOPP project is the catalyst to transform current FGrPP recycling and become the next food-grade recycling success story. PET was first and now it’s the turn of PP.
About Nextek Ltd
Nextek is a global sustainability consultancy that provides strategic advice to regional and multi-national organisations and recycling companies. Launched in 2004, Nextek researches and develops innovative strategies and processes within the recycling ecosystem – from designing recycling plants to developing ground-breaking projects for governments and major organisations. Nextek launched NEXTLOOPP, a two-year 37-strong project, to close the loop on food-grade recycled Polypropylene (rPP). This project incorporates unique technological breakthroughs that include innovative sorting and cutting-edge decontamination technologies.
About Tomra
TOMRA is a Norwegian multinational corporation that manufactures collection and sorting products, such as reverse vending machines for the food, recycling and mining industries. TOMRA is the market leader in its industry with over 100,000 installations in 80+ markets worldwide. Its Recycling Division has pioneered the automation of waste sorting.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211020005464/en/
Contact information
Janine Wood
Email: janinewood@nexteklimited.com
Tel: +44 (0)7831582659
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom